A Study of LY03015 in Healthy Chinese and Caucasian Adult Subjects

Phase 1 Completed 24 enrolled Luye Pharma Group Ltd.

Non-randomizedParallel-groupOpen-labelBasic science

Summary

This is an open-label, single-dose, parallel-group study to evaluate the safety, tolerability and pharmacokinetic characteristics of LY03015 in healthy Chinese and Caucasian adult subjects. The duration of study will be around up to 42 days for each participant, including up to 14 days of screening period, baseline visit, and a 28-day safety assessment period with a 7-day/6-night stay in the clinical research unit.

Timeline

Start: 2026-04-15
Primary completion: 2026-05-08
Completion: 2026-05-27

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	LY03015	Unknown	20 mg	Oral

Indications

No indication recorded.